In June, Novartis’ Kisqali showed it could prolong the lives of breast cancer patients, making it the first in its class to do so. And now, it’s done it again. More: Novartis' Kisqali sharpens survival edge with second ph3 win
read moreA decade ago Congress was up in arms about Chinese crude heparin in the U.S. supply chain. Now they are highly concerned there may not be enough of it. More: Congress hits panic button over potential Chinese heparin shortage as swine
read moreThe Trump administration on Wednesday presented a plan for bringing in cheaper drugs from Canada, reversing years of HHS and FDA opposition to the idea. Pharma’s staunchly opposed, too. But the plan itself might not do much to lower prices—or hurt
read morePfizer and Astellas’ Xtandi and Johnson & Johnson’s Erleada may have big head starts in the prostate cancer market, but Bayer and partner Orion have a new entry—and they’re looking to carve out a share. More: Chasing Pfizer and J&J,
read moreMylan has spent more than $460 million buying Novartis cystic fibrosis products. Now, it wants the plant that makes them. More: Mylan, which bought Novartis CF drugs, circles back for the manufacturing assets Source: fierce
read moreThe drug has been approved under the governing body’s Priority Review designation. More: Nubeqa bags FDA green light Source: News
read more© 1994 - 2023 B.M. Pharmaceuticals